v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Research and development $ 33,333
Costs and Expenses:    
Research and development 3,241,432 4,086,883
General and administrative 3,145,010 2,259,631
Total costs and expenses 6,386,442 6,346,514
Loss from operations (6,353,109) (6,346,514)
Sale of New Jersey net operating loss & tax credits 1,328,470 1,073,289
Other income, net 68,319 227,327
Net loss (4,956,320) (5,045,898)
Preferred stock series B accumulated dividends (210,900) (170,700)
Net loss attributable to common shareholders $ (5,167,220) $ (5,216,598)
Net loss attributable to common shareholders per share - basic and diluted $ (0.03) $ (0.03)
Weighted average common shares outstanding:    
Basic and diluted 203,871,820 191,671,153
Other comprehensive (loss)/income, net of tax    
Unrealized (loss)/gain on securities available-for-sale $ (91,766) $ 523,246
Other comprehensive (loss)/income, net of tax (91,766) 523,246
Comprehensive loss attributable to shareholders $ (5,048,086) $ (4,522,652)

Source